314 related articles for article (PubMed ID: 32842558)
1. Pharmacovigilance of Biopharmaceuticals in Rheumatic Diseases, Adverse Events, Evolution, and Perspective: An Overview.
Rodríguez S; Muñoz A; Bustos RH; Jaimes D
Biomedicines; 2020 Aug; 8(9):. PubMed ID: 32842558
[TBL] [Abstract][Full Text] [Related]
2. Relative risk of tuberculosis in patients with rheumatic diseases managed with anti-tumour necrosis factor-alpha therapy: A nationwide cohort study.
Aydin V; Akici A; Isli F; Aksoy M; Aydin M; Gursoz H
J Clin Pharm Ther; 2019 Aug; 44(4):553-560. PubMed ID: 30763469
[TBL] [Abstract][Full Text] [Related]
3. Biopharmaceuticals for rheumatic diseases in Latin America, Europe, Russia, and India: innovators, biosimilars, and intended copies.
Castañeda-Hernández G; Szekanecz Z; Mysler E; Azevedo VF; Guzman R; Gutierrez M; Rodríguez W; Karateev D
Joint Bone Spine; 2014 Dec; 81(6):471-7. PubMed ID: 24956990
[TBL] [Abstract][Full Text] [Related]
4. Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.
Cantini F; Nannini C; Niccoli L
Open Access Rheumatol; 2009; 1():163-178. PubMed ID: 27789989
[TBL] [Abstract][Full Text] [Related]
5. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.
Rainsford KD; Parke AL; Clifford-Rashotte M; Kean WF
Inflammopharmacology; 2015 Oct; 23(5):231-69. PubMed ID: 26246395
[TBL] [Abstract][Full Text] [Related]
6. Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Husni ME; Deodhar A; Schwartzman S; Chakravarty SD; Hsia EC; Leu JH; Zhou Y; Lo KH; Kavanaugh A
Arthritis Res Ther; 2022 Mar; 24(1):73. PubMed ID: 35313978
[TBL] [Abstract][Full Text] [Related]
7. Long-term golimumab persistence: Five-year treatment retention data pooled from pivotal Phase III clinical trials in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Weinstein CLJ; Meehan AG; Lin J; Briscoe SD; Govoni M
Clin Rheumatol; 2023 Dec; 42(12):3397-3405. PubMed ID: 37751000
[TBL] [Abstract][Full Text] [Related]
8. [Biological therapy for the treatment of rheumatic diseases].
Pierer M; Baerwald C
Internist (Berl); 2008 Aug; 49(8):938-46. PubMed ID: 18587545
[TBL] [Abstract][Full Text] [Related]
9. The use of anti-TNF-alpha therapies for patients with systemic lupus erythematosus. Where are we now?
Lorenzo-Vizcaya A; Isenberg DA
Expert Opin Biol Ther; 2021 May; 21(5):639-647. PubMed ID: 33216641
[TBL] [Abstract][Full Text] [Related]
10. Assessment of Reported Adverse Events After Interchanging Between TNF-α Inhibitor Biosimilars in the WHO Pharmacovigilance Database.
Pauline O; Robert M; Bernardeau C; Hlavaty A; Fusaroli M; Roustit M; Cracowski JL; Khouri C
BioDrugs; 2023 Sep; 37(5):699-707. PubMed ID: 37278971
[TBL] [Abstract][Full Text] [Related]
11. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
Chiu YM; Chen DY
Expert Rev Clin Immunol; 2020 Feb; 16(2):207-228. PubMed ID: 31852268
[No Abstract] [Full Text] [Related]
12. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity.
Gabay C; Cakir N; Moral F; Roux-Lombard P; Meyer O; Dayer JM; Vischer T; Yazici H; Guerne PA
J Rheumatol; 1997 Feb; 24(2):303-8. PubMed ID: 9034987
[TBL] [Abstract][Full Text] [Related]
13. PANLAR consensus statement on biosimilars.
Kowalski SC; Benavides JA; Roa PAB; Galarza-Maldonado C; Caballero-Uribe CV; Soriano ER; Pineda C; Azevedo VF; Avila-Pedretti G; Babini AM; Cachafeiro-Vilar A; Cifuentes-Alvarado M; Cohen SB; Díaz PE; Soto LD; Encalada C; Garro B; Sariego IAG; Guibert-Toledano M; Rodriguez VJK; Lopez MEL; Ortega AP; Russell AS; Santos-Moreno P; Terán IS; Vargas A; Vásquez G; Xavier RM; Firedman DXX; Mysler E; Kay J
Clin Rheumatol; 2019 May; 38(5):1485-1496. PubMed ID: 30915652
[TBL] [Abstract][Full Text] [Related]
14. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Benucci M; Gobbi FL; Guiducci S; Foti R; Mosca M; Goletti D
Semin Arthritis Rheum; 2017 Oct; 47(2):183-192. PubMed ID: 28413099
[TBL] [Abstract][Full Text] [Related]
15. COVID-19 in DMARD-treated patients with inflammatory rheumatic diseases: Insights from an analysis of the World Health Organization pharmacovigilance database.
Dernoncourt A; Schmidt J; Duhaut P; Liabeuf S; Gras-Champel V; Masmoudi K; Bennis Y; Batteux B
Fundam Clin Pharmacol; 2022 Feb; 36(1):199-209. PubMed ID: 33973280
[TBL] [Abstract][Full Text] [Related]
16. The clinical application of etanercept in Chinese patients with rheumatic diseases.
Chou CT
Mod Rheumatol; 2006; 16(4):206-13. PubMed ID: 16906369
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
Ogdie A; de Vlam K; McInnes IB; Mease PJ; Baer P; Lukic T; Gruben D; Kwok K; Wang C; Hsu MA; Maniccia A
RMD Open; 2020 Feb; 6(1):. PubMed ID: 32396519
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-α agents in rheumatic diseases; A systematic review and meta-analysis.
Komaki Y; Yamada A; Komaki F; Kudaravalli P; Micic D; Ido A; Sakuraba A
J Autoimmun; 2017 May; 79():4-16. PubMed ID: 28209290
[TBL] [Abstract][Full Text] [Related]
19. Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries.
Swart J; Giancane G; Horneff G; Magnusson B; Hofer M; Alexeeva Е; Panaviene V; Bader-Meunier B; Anton J; Nielsen S; De Benedetti F; Kamphuis S; Staņēviča V; Tracahana M; Ailioaie LM; Tsitsami E; Klein A; Minden K; Foeldvari I; Haas JP; Klotsche J; Horne AC; Consolaro A; Bovis F; Bagnasco F; Pistorio A; Martini A; Wulffraat N; Ruperto N;
Arthritis Res Ther; 2018 Dec; 20(1):285. PubMed ID: 30587248
[TBL] [Abstract][Full Text] [Related]
20. Secukinumab for rheumatology: development and its potential place in therapy.
Koenders MI; van den Berg WB
Drug Des Devel Ther; 2016; 10():2069-80. PubMed ID: 27445458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
